The P-II/III (REJOICE-Ovarian01) study assesses raludotatug deruxtecan (R-DXd) vs CT to treat Pt-resistant, high-grade ovarian cancer patients (n=650) administered with at least 1 & not >3 previous systemic lines of anticancer treatment in the EU, Asia, North & South America
The study, built on the findings from an ongoing P-I trial, comprises 2 parts where the P-II part evaluates the safety & tolerability of 3 doses (4.8 mg/kg, 5.6 mg/kg, or 6.4 mg/kg) to find recommended dose while the P-III part evaluates the safety & effectiveness of the selected dose
Raludotatug deruxtecan, based on Daiichi Sankyo’s DXd ADC technology, consists of a humanized anti-CDH6 IgG1 mAb & a no. of topoisomerase I inhibitor payloads linked using tetrapeptide-based cleavable linkers
Ref: Merck | Image: Merck
Related News:- Merck’s Winrevair (sotatercept-csrk) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension (PAH)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
